Scoping out Gastroenterology Start-Ups

The field of gastroenterology is tantalizing for device manufacturers because it offers one of the rare screening paradigms in medicine, and therefore, enormous markets. In the US, it's recommended that everyone over the age of 50 be screened for colorectal cancer by a colonoscopy procedure. However, compliance with colorectal screening recommendations is low, less than 50% for colonoscopy, the gold standard for detecting precancerous polyps. GI endoscopy is unusual among screening paradigms in its degree of invasiveness and cost, and that limits access to screening. Medtech start-ups hope to improve upon this state of affairs by offering new technologies to improve the ease, decrease the discomfort, and increase the efficiency of endoscopic procedures.

When it comes to technological innovation, the field of gastroenterology lags other clinical spaces. Gastroenterologists are said to be slow adopters of new technologies, and disruptive innovation seems to come along only every 30 years or so. The last major advance, say some, happened back in 1983 at DDW (Digestive Disease Week), the annual gastroenterology conference, when Olympus Corp. introduced the first CCD sensing camera on the end of an endoscope, enabling the electronic capture of images. Before that, the last major advance was the advent of fiberoptics in 1956. Those technologies advanced image quality, but the basic endoscopy procedure itself--which relies on snaking a semi-rigid hose at the end of which is a visualization tool through five to six feet of twists and turns in a soft organ--has not changed in 50 years. Start-ups are fond of pointing this out, because, with some rare exceptions, it’s been difficult for all but the largest companies—Olympus, Pentax Corp., Fuji Photo Film Co. Ltd.-- to succeed at capturing any part of the market with new technologies, and indeed, there are many start-up and product failures along the way.

The field is tantalizing because it offers one of the rare screening paradigms in medicine, and therefore, enormous markets. In...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

‘Eyes – A Window Into The Heart’: Retinal AI Tool Predicts Future Risk Of Heart Attack And Stroke

 

A deep-learning AI-based retinal image scanning tool can predict the risk of cardiovascular events over a 10-year period with 70% accuracy. The test is comparable to routine GP health checks, researchers from the University of Dundee have shown.

Digital Health Roundup: Autonomous Robots, Medtronic’s Surgeon School, Sleep & FDA Rules

In this week's Digital Health Roundup, Medtech Insight's team discusses progress on autonomous surgery, Medtronic's new partnership with IRCAD, FDA cybersecurity news, and C-suite interviews with OpenWater, Flow Neuroscience and EnsoData.

Whoops! FDA Says Company Marketed Unauthorized Device. The Company Says The FDA Is Wrong

 

A recent FDA warning letter claims a Boston firm that specializes in wearable technology marketed a blood pressure device without agency approval. The company rejects the assertion and says the agency is out of step with federal law.